Jubilant Pharmova’s arm completes studies using novel oral formulation of Remdesivir

19 Apr 2021 Evaluate

Jubilant Pharmova’s subsidiary company -- Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of COVID-19 against the available injectable formulation of the antiviral drug in India. Jubilant has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI). Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients.

The proposed oral treatment is expected to be for 5 days, duration similar to the injectable dosage form. Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with COVID-19 requiring hospitalization.

Jubilant Pharmova (formerly Jubilant Life Sciences Limited) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1076.40 7.20 (0.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×